US$ 25.44
daily oral glp-1 receptor agonist orforglipron for adults with obesity Orforglipron Shows Positive Efficacy, Tolerability
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 40

doi:10.1016/j.bbrc.2014.03.004 52

Results of cardiovascular safety studies have not shown any indication of cardiovascular harm, with possible suggestion of cardiovascular benefit
02165-8/asset/22b8c416-d38b-4d11-98e3-804944d9ec9b/main.assets/gr2b_lrg.jpg)
Conclusion This paper outlines the complex relationship between GLP-1 and delayed gastric emptying, particularly gastroparesis, and its implications for pulmonary aspiration during anesthesia for various cardiac procedures and surgeries

Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: a retrospective real-life study in 131 patients
